Amplia Therapeutics: FDA Granted Fast-Track Designation to Amplia's Lead Drug Narmafotinib in Advanced Pancreatic Cancer >ATX.AU

Dow JonesSep 20 07:17

FDA FAST TRACK DESIGNATION FOR NARMAFOTINIB IN ADVANCED PANCREATIC CANCER

Yahoo FinanceSep 20 07:13

Amplia Therapeutics: Advancing Pancreatic Cancer Treatment | ASX:ATX

Proactive InvestorsAug 22 00:49

Amplia Therapeutics Receives Patent for Narmafotinib in Europe, Japan

MT NewswiresAug 7 10:37

Amplia Therapeutics Shares Rally 17% on Fourth Confirmed Response in Pancreatic Cancer Trial

MT NewswiresAug 6 10:43

2 ASX Biotech Shares Rocketing More Than 40% on Big News

The Motley FoolJul 25 13:15